Souhaitez-vous accéder aux communiqués récents ?

New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of...

Medical Oncologist Peter Mathern Joins American Oncology Network Partner Practice, Cancer and Blood Specialists of Arizona in Flagstaff

Oncology Consultants Welcomes Dr. Cesar De Las Casas

Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...

Rising malnutrition among infants, oncology patients and older adults, along with healthcare investment and product advances, is driving market growth.

OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their last dose of Ampligen®...

$8B Curium-Lantheus deal creates a global radiopharmaceutical leader, expanding reach across oncology, neurology and cardiology in 70+ countries.

First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA...

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in...

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...